 SAN DIEGO, March 31, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a late-stage targeted oncology company, today announced its Board of Directors has elected a new independent director, Ms. Shalini Sharp. 